Viracta TherapeuticsVIRX
13F holders, Q1 2025 (March 31)7holders −25
1new positions
26sold out
$0.02avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Viracta Therapeutics Inc. (VIRX) in their 13F filings, down 25 from Q4 2024. 1 opened new positions and 26 sold out. The largest holders were XTX Topco Ltd ($2K), United Capital Financial Advisors, LLC ($860) and WealthTrust Axiom LLC ($384).
- Company
- Viracta Therapeutics Inc.
- CUSIP
- 92765F108
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 26 | $569K |
All 13F filers, Q4 2024 → Q1 2025: 83,421 shares bought and 3,527,329 shares sold, net −3,443,908 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| XTX Topco Ltd | 0.00% | Add +530.6% | 93,391 | $2K |
| United Capital Financial Advisors, LLC | 0.00% | No change | 42,995 | $860 |
| WealthTrust Axiom LLC | 0.00% | No change | 16,396 | $384 |
| Baader Bank Aktiengesellschaft | 0.00% | Add +41.0% | 15,265 | $283 |
| RP Management, LLC | 0.00% | No change | 3,700 | $74 |
| Simplex Trading, LLC | 0.00% | New | 400 | $0 |
| Parallel Advisors, LLC | 0.00% | No change | 8 | $0 |
"% of holder's portfolio" is VIRX's weight in each manager's 13F, not the share of Viracta Therapeutics Inc. the manager owns.